Literature DB >> 23763009

Translocated intrauterine contraceptive device: experiences of two medical centers with risk factors and the need for surgical treatment.

Hatice Ender Soydinc1, Mehmet Siddik Evsen, Fatmanur Caça, Muhammet Erdal Sak, Mehmet Zeki Taner, Sibel Sak.   

Abstract

OBJECTIVE: To present experiences of 21 patients with a translocated intrauterine contraceptive device (IUD) who required surgical treatment and to discuss the diagnosis, surgical management, and complications of such cases. STUDY
DESIGN: The cases of 21 patients who were hospitalized with the diagnosis of translocated IUD and had surgical treatment were analyzed retrospectively.
RESULTS: The mean age of the patients was 25.7 (range, 20-35). Of the 21 patients, 17 (81%) were in puerperium. IUDs were inserted by trained midwife nurses in 17 cases (81%). Severe lower abdominal pain was reported by 16 patients (76%) during the insertion procedure. At the time of diagnosis, 13 patients (62%) presented with lower abdominal pain. Surgical treatments included laparoscopic surgery (67%), laparotomy, colpotomy, and hysteroscopy. All of the removed IUDs were TCu-380A models. The most frequent complication due to translocation of the IUD was pelvic abscess (38%).
CONCLUSION: The incidence of IUD translocations was significantly high in the puerperal period and for insertions performed by educated midwife nurses. Uterine perforation must be taken into consideration when there are complaints of unusually severe abdominal pain during the insertion procedure. Surgical treatment is necessary because of the potential complications of extracavitary IUDs.

Entities:  

Mesh:

Year:  2013        PMID: 23763009

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  1 in total

1.  Importance of abdominal X-ray to confirm the position of levonorgestrel-releasing intrauterine system: A case report.

Authors:  Aki Maebayashi; Kanoko Kato; Nobuki Hayashi; Masaji Nagaishi; Kei Kawana
Journal:  World J Clin Cases       Date:  2022-05-26       Impact factor: 1.534

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.